MedPath

KYMAB LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

12

Active:6
Completed:5

Trial Phases

2 Phases

Phase 1:9
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
9 (81.8%)
Phase 2
2 (18.2%)

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

Phase 2
Completed
Conditions
Atopic Dermatitis
Eczema
Interventions
First Posted Date
2021-11-23
Last Posted Date
2025-07-03
Lead Sponsor
Kymab Limited
Target Recruit Count
390
Registration Number
NCT05131477
Locations
🇺🇸

Investigative Site Number: 1018, Fremont, California, United States

🇺🇸

Investigative site #1022, Sacramento, California, United States

🇺🇸

Investigative Site Number: 1006, Boca Raton, Florida, United States

and more 98 locations

A Study of Subcutaneous KY1005 in Healthy Volunteers

Phase 1
Completed
Conditions
Immune System Diseases
Interventions
First Posted Date
2020-06-29
Last Posted Date
2021-09-30
Lead Sponsor
Kymab Limited
Target Recruit Count
24
Registration Number
NCT04449939
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1
Terminated
Conditions
Squamous Cell Carcinoma of Head and Neck
Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Esophageal Cancer
Gastric Cancer
Melanoma
Renal Cell Carcinoma
Pancreatic Cancer
Cervical Cancer
Triple Negative Breast Cancer
Interventions
First Posted Date
2019-02-04
Last Posted Date
2025-04-02
Lead Sponsor
Kymab Limited
Target Recruit Count
222
Registration Number
NCT03829501
Locations
🇺🇸

Kymab investigational site 1109, Duarte, California, United States

🇺🇸

Kymab investigational site 1102, New Haven, Connecticut, United States

🇺🇸

Kymab investigational site 1108, Orlando, Florida, United States

and more 19 locations

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: Placebo
First Posted Date
2018-11-27
Last Posted Date
2023-01-27
Lead Sponsor
Kymab Limited
Target Recruit Count
89
Registration Number
NCT03754309
Locations
🇩🇪

Kymab investigational site 106, Kiel, Germany

🇩🇪

Kymab investigational site 113, Leipzig, Germany

🇵🇱

Kymab investigational site 207, Gdansk, Poland

and more 16 locations

A Study of KY1005 in Healthy Volunteers

Phase 1
Completed
Conditions
Immune System Diseases
Interventions
Drug: Placebo
First Posted Date
2017-05-19
Last Posted Date
2019-08-29
Lead Sponsor
Kymab Limited
Target Recruit Count
64
Registration Number
NCT03161288
Locations
🇳🇱

Centre for Human Drug Research, Leiden, Netherlands

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.